Wichtige Dokumente

Gesamtdokumentation anzeigen

L3045

β-Lactamase from Pseudomonas fluorescens

Name: β-Lactamase from <I>Pseudomonas fluorescens</I>
Brand: SIGMA

lyophilized powder, recombinant, expressed in E. coli

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Über diesen Artikel

UNSPSC Code:

12352204

NACRES:

NA.54

EG-Nummer:

3.5.2.6 (BRENDA, IUBMB)

MDL number:

MFCD00131819

Recombinant:

expressed in E. coli

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Eigenschaften

recombinant

expressed in E. coli

Quality Level

200

form

lyophilized powder

enzyme activity

7.5-15 units/mg solid

shipped in

wet ice

storage temp.

2-8°C

Beschreibung

Physical form

Lyophilized powder containing potassium phosphate and sodium bicarbonate

Other Notes

One unit will hydrolyze 1.0 μmole of benzylpenicillin per minute at pH 7.0 at 25 °C

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

010M1350

129K1199

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Molecular characterization of extended-spectrum beta-lactamases and its correlation with clinical laboratory standards institute interpretive criteria for disk diffusion susceptibility testing in enterobacteriaceae isolates in Thaialnd.

Teerawit Tangkoskul et al.

The Southeast Asian journal of tropical medicine and public health, 43(6), 1461-1469 (2013-02-19)

We performed extended-spectrum beta-lactamase (ESBL) phenotypic testing and molecular characterization of three ESBL genes (TEM, SHV and CTX-M) and susceptibility testing by Clinical Laboratory Standards Institute (CLSI) disk diffusion method against three cephalosporins (ceftriaxone, ceftazidime, cefepime) and a cephamycin (cefoxitin)

Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.

Siriluck Anunnatsiri et al.

The Southeast Asian journal of tropical medicine and public health, 43(5), 1169-1177 (2013-02-26)

Escherichia coli producing extended spectrum beta-lactamase (ESBL) has emerged as a worldwide, public health problem. The aims of this study were to determine the incidence of ESBL-producing E. coli septicemia and evaluate the factors associated with the infection and the

Notes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase--Denver, Colorado, 2012.

MMWR. Morbidity and mortality weekly report, 62(6), 108-108 (2013-02-15)

On August 16, 2012, the Colorado Department of Public Health and Environment was notified of two patients at an acute-care hospital in Denver with carbapenem-resistant Enterobacteriaceae (CRE), specifically Klebsiella pneumoniae (CRKP), isolated from respiratory specimens during July-August. Both isolates produced

Alle zugehörigen Dokumente anzeigen

Global Trade Item Number

SKU	GTIN
L3045-5UN	04061833950807